Stent Implantation for Superior Vena Cava Syndrome of Malignant Cause

Abstract

Purpose The purpose of this paper is the retrospective analysis of endovascular therapy for the treatment of superior vena cava syndrome (SVCS) of malignant cause. This study focuses on the effectiveness of the therapy regarding the duration of remission, symptom control and practicability.

Materials and Methods From January 2003 to November 2012, therapeutic implantation of one or more stents was performed in 141 patients suffering from SVCS. The medical history was retrospectively researched using digitalized patient files. If those were incomplete, secondary research was conducted using the cancer registry of the General Hospital Nuremberg, the cancer registry of the tumor center at Friedrich-Alexander-University Erlangen-Nuremberg (FAU) or information given by physicians in private practice. This data was collected using Microsoft Office Excel^® and statistically analyzed using IBM SPSS Statistics 22^®.

Results 168 stents were implanted in 141 patients (median age: 64.6 years; range: 36 – 84), 86 being male and 55 being female. In 121 patients, SVCS was caused by lung cancer (85.8 %), in 9 patients by mediastinal metastasis of an extrathoracic carcinoma (6.4 %), in 3 patients by mesothelioma of the pleura (2.1 %) and in 1 patient by Hodgkin’s disease (0.7 %). There was no histological diagnosis in 7 cases (4.9 %). The primary intervention was successful in 138 patients (97.9 %). Immediate thrombosis in the stent occurred in the remaining 3 cases. Recurrence of SVCS was observed in 22 patients (15.6 %), including 5 early and 17 late occlusions. Stent dislocation or breakage was not observed. As expected, the survival after implantation was poor. The median survival was 101 days, and the median occlusion-free survival was 80 days.

Conclusion The symptomatic therapy of SVCS with endovascular stents is effective and safe. Despite effective symptom control and a low rate of recurrence, the patients' prognosis is poor.

Key Points: 

• Patients with SVCS of malignant cause have a poor prognosis.

• Lung cancer is the most common cause for SVCS.

• Endovascular therapy is safe and effective.

Citation Format

• Büstgens FA, Loose R, Ficker JH et al. Stent Implantation for Superior Vena Cava Syndrome of Malignant Cause. Fortschr Röntgenstr 2017; 189: 423 – 430

Key words

malignant superior vena cava syndrome - endovascular stent - lung carcinoma - poor outcome

• References

• 1 Sigwart U. Puel J. Mirkovitch V. et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316: 701-706
• 2 van Buuren F. 25. Bericht über die Leistungszahlen der Herzkatheterlabore in der Bundesrepublik Deutschland. Der Kardiologe 2010; 4: 502-508
• 3 Fusaro M. Cassese S. Ndrepepa G. et al. Drug-eluting stents for revascularization of infrapopliteal arteries: updated meta-analysis of randomized trials. JACC Cardiovasc Interv 2013; 6: 1284-1293
• 4 Scheinert D. Katsanos K. Zeller T. et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. Journal of the American College of Cardiology 2012; 60: 2290-2295
• 5 Charnsangavej C. Carrasco CH. Wallace S. et al. Stenosis of the vena cava: preliminary assessment of treatment with expandable metallic stents. Radiology 1986; 161: 295-298
• 6 Rosch J. Bedell JE. Putnam J. et al. Gianturco expandable wire stents in the treatment of superior vena cava syndrome recurring after maximum-tolerance radiation. Cancer 1987; 60: 1243-1246
• 7 Nicholson AA. Ettles DF. Arnold A. et al. Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol 1997; 8: 781-788
• 8 Zollikofer CL. Antonucci F. Stuckmann G. et al. Use of the Wallstent in the venous system including hemodialysis-related stenoses. Cardiovasc Intervt Radiol 1992; 15: 334-341
• 9 Hennequin LM. Fade O. Fays JG. et al. Superior vena cava stent placement: results with the Wallstent endoprosthesis. Radiology 1995; 196: 353-361
• 10 Reechaipichitkul WTS. Etiology and outcome of superior vena cava (SVC) obstruction in adults. Southeast Asian J Trop Med Public Health 2004; 35: 453-457
• 11 Qanadli SD. El Hajjam M. Mignon F. et al. Subacute and chronic benign superior vena cava obstructions: endovascular treatment with self-expanding metallic stents. Am J Roentgenol 1999; 173: 159-164
• 12 Rowell NP. Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol (R Coll Radiol) 2002; 14: 338-351
• 13 Escalante CP. Causes and management of superior vena cava syndrome. Oncology (Williston Park) 1993; 7: 61-68 discussion 71–62, 75–67
• 14 Kee ST. Kinoshita L. Razavi MK. et al. Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. Radiology 1998; 206: 187-193
• 15 Furui S. Sawada S. Kuramoto K. et al. Gianturco stent placement in malignant caval obstruction: analysis of factors for predicting the outcome. Radiology 1995; 195: 147-152
• 16 Irving JD. Dondelinger RF. Reidy JF. et al. Gianturco self-expanding stents: clinical experience in the vena cava and large veins. Cardiovascular and interventional radiology 1992; 15: 328-333
• 17 Picquet J. Blin V. Dussaussoy C. et al. Surgical reconstruction of the superior vena cava system: indications and results. Surgery 2009; 145: 93-99
• 18 Cho Y. Gwon DI. Ko GY. et al. Covered stent placement for the treatment of malignant superior vena cava syndrome: is unilateral covered stenting safe and effective?. Korean J Radiol 2014; 15: 87-94
• 19 Suzuki K. Asamura H. Watanabe S. et al. Combined resection of superior vena cava for lung carcinoma: prognostic significance of patterns of superior vena cava invasion. Ann Thorac Surg 2004; 78: 1184-1189 discussion 1184–1189
• 20 Smayra T. Otal P. Chabbert V. et al. Long-term results of endovascular stent placement in the superior caval venous system. Cardiovascular and interventional radiology 2001; 24: 388-394
• 21 Rice TW. Rodriguez RM. Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine 2006; 85: 37-42
• 22 Schifferdecker B. Shaw JA. Piemonte TC. et al. Nonmalignant superior vena cava syndrome: pathophysiology and management. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions 2005; 65: 416-423
• 23 Rodrigues CI. Njo KH. Karim AB. Hypofractionated radiation therapy in the treatment of superior vena cava syndrome. Lung cancer 1993; 10: 221-228
• 24 Chan RC. Chan YC. Cheng SW. Mid- and long-term follow-up experience in patients with malignant superior vena cava obstruction. Interactive cardiovascular and thoracic surgery 2013; 16: 455-458
• 25 Armstrong BA. Perez CA. Simpson JR. et al. Role of irradiation in the management of superior vena cava syndrome. International journal of radiation oncology, biology, physics 1987; 13: 531-539
• 26 Urban T. Lebeau B. Chastang C. et al. Superior vena cava syndrome in small-cell lung cancer. Arch Intern Med 1993; 153: 384-387
• 27 Wurschmidt F. Bunemann H. Heilmann HP. Small-Cell Lung-Cancer with and without Superior Vena-Cava Syndrome – a Multivariate-Analysis of Prognostic Factors in 408 Cases. Int J Radiat Oncol 1995; 33: 77-82
• 28 Nguyen NP. Borok TL. Welsh J. et al. Safety and effectiveness of vascular endoprosthesis for malignant superior vena cava syndrome. Thorax 2009; 64: 174-178
• 29 Uberoi R. Patel R. Cox P. et al. CIRSE Quality Assurance Guidelines for Superior Vena Cava Stenting in Malignant Disease. 2015 https://eu-csite-storage-prod.s3.amazonaws.com/www-cirse-org/files/files/CIRSE_QA_Guidelines_for_SVC_Stenting_in_Malignant_Disease_Revision_Uberoi_2016.pdf
• 30 Monaco RG. Bertoni H. Pallota G. et al. Use of self-expanding vascular endoprostheses in superior vena cava syndrome. European Journal of Cardio-Thoracic Surgery 2003; 24: 208-211